MedicinefromArs Technica1 day agomRNA cancer vaccine shows protection at 5-year follow-up, Moderna and Merck saymRNA vaccine combined with Keytruda reduced five-year recurrence or death by 49% versus Keytruda alone in high-risk melanoma.